Issue 3/2017
Content (12 Articles)
What We Know About Stage II and III Colon Cancer: It’s Still Not Enough
Alberto Puccini, Martin D. Berger, Wu Zhang, Heinz-Josef Lenz
Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors
César Serrano, Suzanne George, Claudia Valverde, David Olivares, Alfonso García-Valverde, Cristina Suárez, Rafael Morales-Barrera, Joan Carles
Cancer Immunotherapy with Cytokine-Induced Killer Cells
Juan J. Mata-Molanes, Manuel Sureda González, Belén Valenzuela Jiménez, Elena Mª Martínez Navarro, Antonio Brugarolas Masllorens
Immune Checkpoint Inhibitor-Induced Colitis: Diagnosis and Management
Caroline Prieux-Klotz, Marie Dior, Diane Damotte, Johann Dreanic, Bertrand Brieau, Catherine Brezault, Vered Abitbol, Stanislas Chaussade, Romain Coriat
Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis
Xiu-Wei Zhang, Yu-Xiang Ma, Yang Sun, Yu-Bo Cao, Qin Li, Chong-An Xu
A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies
Trisha M. Wise-Draper, Ganesh Moorthy, Mohamad A. Salkeni, Nagla Abdel Karim, Hala Elnakat Thomas, Carol A. Mercer, M. Shalaan Beg, Sue O’Gara, Olugbenga Olowokure, Hassana Fathallah, Sara C. Kozma, George Thomas, Olivier Rixe, Pankaj Desai, John C. Morris
Long-term Duration of First-Line Axitinib Treatment in Advanced Renal Cell Carcinoma
Brian I. Rini, Victor Gruenwald, Eric Jonasch, Mayer N. Fishman, Yoshihiko Tomita, M. Dror Michaelson, Jamal Tarazi, Laura Cisar, Subramanian Hariharan, Angel H. Bair, Brad Rosbrook, Thomas E. Hutson
Detection of HER2 Amplification in Circulating Tumor Cells of HER2-Negative Gastric Cancer Patients
Yuji Mishima, Satoshi Matsusaka, Keisho Chin, Mariko Mikuniya, Sayuri Minowa, Tomoko Takayama, Harumi Shibata, Ryoko Kuniyoshi, Mariko Ogura, Yasuhito Terui, Nobuyuki Mizunuma, Kiyohiko Hatake
CRNDE Expression Positively Correlates with EGFR Activation and Modulates Glioma Cell Growth
Karrie Mei-Yee Kiang, Xiao-Qin Zhang, Grace Pingde Zhang, Ning Li, Stephen Yin Cheng, Ming-Wai Poon, Jenny Kan-Suen Pu, Wai-Man Lui, Gilberto Ka-Kit Leung
Circulating Tumor DNA Measurement by Picoliter Droplet-Based Digital PCR and Vemurafenib Plasma Concentrations in Patients with Advanced BRAF-Mutated Melanoma
Fanny Garlan, Benoit Blanchet, Nora Kramkimel, Alicja Puszkiel, Jean-Louis Golmard, Gaelle Noe, Nicolas Dupin, Pierre Laurent-Puig, Michel Vidal, Valerie Taly, Audrey Thomas-Schoemann
Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer
Esther S. Kim, Lesley J. Scott
Erratum to: Ongoing Response in BRAF V600E-Mutant Melanoma After Cessation of Intermittent Vemurafenib Therapy: A Case Report
Andrew J. Dooley, Avinash Gupta, Mark R. Middleton